Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. - Wikidata - awgldk - TriplyDB

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

http://www.wikidata.org/entity/Q34633455

about

Melanoma: from melanocyte to genetic alterations and clinical options Systemic treatments for metastatic cutaneous melanoma Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Recent advances in the treatment of melanoma with BRAF and MEK inhibitors Adjuvant Therapy of Uveal Melanoma: Current Status Optimal management of metastatic melanoma: current strategies and future directions Beyond BRAF: where next for melanoma therapy?Targeting the RAS oncogene.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.Functional profiling of live melanoma samples using a novel automated platform A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date MEK and the inhibitors: from bench to bedside.The MAPK pathway as an apoptosis enhancer in melanoma.BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies Genetic and pharmacologic inhibition of Tpl2 kinase is protective in a mouse model of ventilator-induced lung injury.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.Targeting mutant NRAS signaling pathways in melanoma.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

P2860

Q21284811-CB66470A-448E-4BAC-BBAD-8E64DE66EA6B Q24194804-60BA5033-9DA7-4411-A090-63B2F69E8B90 Q24303940-7F1489FB-CEC0-47C3-8A3F-9F30068D1801 Q24596266-A9931393-4B6C-4656-AFBF-F13892378582 Q26747247-73534027-574C-4966-A2E9-B13288C51FDC Q26778769-4DE6F25A-726B-4866-86C6-C4E328D1837B Q26865325-37AE4854-F333-42D1-9D4D-5F70B00A0D85 Q26997338-A8337064-F3D9-4240-8B81-9E9A9E977A1B Q27006853-6D428929-2A17-4EF3-9C3F-137D2AF98789 Q27687198-158907E9-CAF8-40A4-9B2A-837E4569C73F Q27851856-949CB41F-A748-45A2-B019-81907204921E Q27852623-13A72E05-DA45-4388-90EB-F6B722DE5312 Q27853026-8EB0AF76-223B-485B-987F-E556F2FF1DA9 Q28484649-30CCF394-7541-4385-9AC6-30EEAD7D57AF Q33439877-A376922F-E7B8-49E7-A9B5-8EF63A3E72D1 Q33729778-51701E89-8062-47D0-BE9B-70CD972FA21A Q33775322-074FA885-B0C9-443B-BB13-BF0E9649FE44 Q33887664-D875CCC4-A5B7-45DF-A256-7515CD73078C Q34036341-B5576D0A-3B42-450B-99AF-7919B2044511 Q34104135-AE08EB59-C4FF-482D-A14A-A9D55282CD07 Q34374407-B1FEE19A-1AED-47B8-82C8-9FC451E73A09 Q34417585-B4BAEFFD-2820-4E29-84B2-10D68BF36F4B Q34524746-7E69EC06-153A-4854-AC33-5A1A17C35A25 Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15 Q35657842-C666B1C2-0A5E-4A4F-8D07-143A6D73C728 Q35859282-7696D4C5-0593-4036-8626-4F6CD9D82A1F Q35883560-EEDF0C40-0A82-4E18-BF04-976FAE27003A Q35915107-CF8CB286-961A-4859-A174-2205A3355AD0 Q36092931-FC72555F-4634-4BC4-B7E6-A90C9BD871D2 Q36141097-14D12995-0170-4C46-B46C-E9E4666AF374 Q36280358-C984E4D3-F451-4D50-80F8-5395166C7A71 Q36414093-5784444C-3C6F-44A7-9D4E-ADA1BA018F97 Q36475286-6E90B1FA-F289-4DE6-849D-A5716B8DC544 Q36507554-A4F9C761-BCBF-4853-8997-8A05A93867FA Q36553791-C521589A-F692-463C-8250-3EFEA3303BB4 Q36563521-1CD04578-8A3C-44E1-96AF-6D8F65873E2C Q36694942-BD0DC6F1-7971-4F34-9D18-5EB75A9E4712 Q36851487-4E520C55-C387-442B-BD7C-B9CF870451EE Q36902066-A77D260E-28E0-4F8B-BCA8-D2BA8F880DC2 Q36916468-019C1123-54C5-479B-A3A1-250BA58318A7

P2860

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

http://www.wikidata.org/entity/Q34633455

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@ast

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@en

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@nl

type

label

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@ast

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@en

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@nl

prefLabel

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@ast

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@en

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@nl

P1433

Q34633455-0E48118E-BF0D-43CA-9DCE-0CFF539BDF1E

P1476

Q34633455-C1474189-C578-4348-B36B-F22E5B1EB720

P2093

Q34633455-2C3E8269-7A86-4612-83D1-CCFB3E12A37B

Q34633455-42BF3413-7EA7-4A65-898D-61C5C2DF3E55

Q34633455-5FE490BA-22E8-4C73-B64B-C7C8F74F904B

Q34633455-70DE0D67-7B96-472B-8258-9A04B17DDF9E

Q34633455-8CCBF604-0A35-47FA-A1AD-9DFA88B4D7DE

Q34633455-94A34B42-52CA-459C-9526-E9E07EE0E818

Q34633455-B6847C47-FEB9-48D8-A3C4-E3939337DDED

Q34633455-BE3D227C-93BF-469F-A600-F1F939120654

Q34633455-FD0EB8A0-F184-4CC0-A340-99F76F986CA7

P2860

Q34633455-014221D4-D762-4A70-8A9C-56008B8D0B17

Q34633455-05D830A1-C6B4-45FD-8667-216FB7B35B89

Q34633455-0974BC5A-B509-4672-AABF-BFE2DBEB573E

Q34633455-0BFAA75E-527C-4FB1-A54B-F7B7D072EAB9

Q34633455-10326627-D5E8-406A-8505-36324C915766

Q34633455-1051E6FB-B73B-4824-B8C8-9F239218FCBC

Q34633455-11981D6E-3431-4592-8E08-CA9C966C8EBA

Q34633455-21DAE333-5314-41B3-A401-10CA0544F988

Q34633455-2CCD9326-362B-404C-922D-ADE7377A85D8

Q34633455-3931C54E-86BD-4D7A-ADDB-C8C3230DFAE0

P304

Q34633455-9FE34D13-56EB-43D6-953E-D1B6E7DA2B9F

P31

Q34633455-0DE60FA9-DB8F-45DA-B635-72A24FDED66F

P356

Q34633455-C923BC60-6295-45D9-975A-004A132C8B4C

P407

Q34633455-07D81819-D524-4225-81B4-246F3BB08950

P433

Q34633455-D1A01D8C-B971-4F24-AAE9-C1D9E33630EC

P478

Q34633455-5C36286A-130A-4939-920F-6DE9A2396A7B

P50

Q34633455-2F8A2AC1-107A-452B-A23E-0275C78E2A01

Q34633455-8543FC26-BFE1-4975-9757-298298FDEFB9

P577

Q34633455-120707AB-6C16-4CBC-B6D6-6C8EE6F09793

P698

Q34633455-54D2CF22-33D1-4377-9953-50F3D1EE5EE2

P921

Q34633455-50080ED7-3C92-4827-96D8-16FA022134A5

Q34633455-DA7A11B9-16B7-46E0-87DF-D3CC382D5738

P932

Q34633455-6AB884FE-93F6-4778-96CC-29520EC0EAC3

P356

1078-0432.CCR-11-1491

P1433

Clinical Cancer Research

P1476

Phase II, open-label, randomiz ...... tients with advanced melanoma.

@en

P2093

James Larkin

http://www.w3.org/2001/XMLSchema#string

Jeff Sosman

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Karin Kemsley

http://www.w3.org/2001/XMLSchema#string

Mark Middleton

http://www.w3.org/2001/XMLSchema#string

Mireille Cantarini

http://www.w3.org/2001/XMLSchema#string

Peter Hersey

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

Victoria Zazulina

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Hyperactive Ras in developmental disorders and cancer

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Clinical experience of MEK inhibitors in cancer therapy.

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

P304

555-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1491

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Robert

P577

2011-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22048237

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3549298

http://www.w3.org/2001/XMLSchema#string